Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples